Imaging studies in drug development: Parkinson's disease

Drug Discovery Today: Technologies

Volumn 2, Issue 4, 2005, Pages 317-321

  Brooks, David J ^a   Lammertsma, Adriaan A ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ADENOSINE A2A RECEPTOR; ALTROPANE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN RECEPTOR; CARBIDOPA; CARBON 11; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; FLUORINE 18; IODINE 123; ISTRADEFYLLINE; LEVODOPA; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NEUROPROTECTIVE AGENT; NOMIFENSINE; NORADRENALIN; OXYGEN 15; PHENETHYLAMINE; SEROTONIN; TECHNETIUM 99M; TROPANE DERIVATIVE; UNINDEXED DRUG;

BRAIN FUNCTION; BRAIN METABOLISM; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE COURSE; DOPAMINE BRAIN LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG UPTAKE; ENZYME ACTIVITY; GENE TARGETING; HUMAN; NEUROIMAGING; NEUROPROTECTION; PARKINSON DISEASE; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 30944443736     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2005.11.001     Document Type: Review

References (28)

1. M. Hutchinson et al. MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIRRIM) Neuroimage 20 2003 1899-1902
2. A. Schrag et al. Differentiation of atypical parkinsonian syndromes with routine MRI Neurology 54 2000 697-702
3. K. Seppi et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy Neurology 60 2003 922-927
4. D.J. Brooks Neuroimaging in Parkinson's disease NeuroRx 1 2004 243-254
5. D.J. Brooks Positron emission tomography and single-photon emission computed tomography in central nervous system drug development NeuroRx 2 2005 226-236
6. D.J. Brooks et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease Exp. Neurol. 184 2003 S68-S79
7. F.J.G. Vingerhoets et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann. Neurol. 41 1997 58-64
8. C.S. Lee et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease Ann. Neurol. 47 2000 493-503
9. M. Doder et al. Tremor in Parkinson's disease and serotonergic dysfunction: An (11)C-WAY 100635 PET study Neurology 60 2003 601-605
10. R.B. Banati et al. PK ('peripheral benzodiazepine')-binding sites in the CNS indicate early and discrete brain lesions: Microautoradiographic detection of [3H]PK11195 binding to activated microglia J. Neurocytol. 26 1997 77-82
11. A. Gerhard et al. In vivo imaging of activated microglia with [C-11] PK11195 positron emission tomography (PET) in idiopathic and atypical Parkinson's disease Neurology 56 Suppl. 3 2001 A270
12. A. Gerhard et al. Microglial activation in Parkinson's disease - its longitudinal course and correlation with clinical parameters: An [11C](R)-PK11195 PET study Neurology 62 Suppl. 5 2004 A432
13. Y. Ouchi et al. Microglial activation and dopamine terminal loss in early Parkinson's disease Ann. Neurol. 57 2005 168-175
14. A. Gerhard et al. Microglial activation in Parkinson's disease - its longitudinal course and correlation with clinical parameters: An [11C](R)-PK11195 PET study Neurology 62 Suppl. 5 2004 A432
15. C.D. Ward Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study J. Neurol. Neurosurg. Psychiatry 57 1994 217-220
16. D.J. Brooks Imaging end points for monitoring neuroprotection in Parkinson's disease Ann. Neurol. 53 3 Suppl. 1 2003 S110-S119
17. Parkinson Study Group Dopamine transporter brain imaging to assess the effects of Pramipexole vs levodopa Parkinson disease progression JAMA 287 2002 1653-1661
18. A.L. Whone et al. Slower progression of PD with ropinirol versus L-dopa: the REAL-PET study Ann. Neurol. 54 2003 93-101
19. J.E. Ahlskog Slowing Parkinson's disease progression: Recent dopamine agonist trials Neurology 60 2003 381-389
20. B. Ravina et al. The role of radiotracer imaging in Parkinson's disease Neurology 64 2005 208-215
21. C.R. Freed et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease N. Engl. J. Med. 344 2001 710-719
22. S.S. Gill et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat. Med. 9 2003 589-595
23. C.W. Olanow et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease Ann. Neurol. 54 2003 403-414
24. C.J. Bench et al. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): A dose ranging study with the reversible inhibitor Ro 19-6327 Eur. J. Clin. Pharmacol. 40 1991 169-173
25. E. Hirani et al. Evaluation of [4-O-Methyl-C-11]KW-6002 as a potential PET ligand for mapping central adenosine A(2A) receptors in rats Synapse 42 2001 164-176
26. G.V. Sawle et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease Neurology 44 1994 1292-1297
27. H.M. Ruottinen et al. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease J. Neural. Transm. Park. Dis. Dement. Sect. 10 1995 91-106
28. P. Piccini et al. Dopamine release from nigral transplants visualised in vivo in a Parkinson's patient Nat. Neurosci. 2 1999 1137-1140